Equillium Stock (NASDAQ:EQ)


RevenueOwnershipFinancialsChart

Previous Close

$0.60

52W Range

$0.56 - $3.25

50D Avg

$0.84

200D Avg

$1.16

Market Cap

$21.54M

Avg Vol (3M)

$173.39K

Beta

1.83

Div Yield

-

EQ Company Profile


Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

45

IPO Date

Oct 12, 2018

Website

EQ Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 24
Upfront Payment Amortization$1.00M

Fiscal year ends in Dec 23 | Currency in USD

EQ Financial Summary


Dec 23Dec 22Dec 21
Revenue$36.08M$15.76M-
Operating Income$-14.52M$-62.08M$-37.79M
Net Income$-13.34M$-107.71M$-38.98M
EBITDA$-14.52M$-15.98M$-37.79M
Basic EPS$-0.38$-3.19$-1.35
Diluted EPS$-0.38$-3.19$-1.35

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 09May 07, 09 | 5:00 PM
Q4 08Feb 13, 09 | 5:00 PM
Q2 08Jul 30, 08 | 5:00 PM

Peer Comparison


TickerCompany
CUECue Biopharma, Inc.
BCABBioAtla, Inc.
HOOKHOOKIPA Pharma Inc.
KTTAPasithea Therapeutics Corp.
SPROSpero Therapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
MNPRMonopar Therapeutics Inc.
ANTXAN2 Therapeutics, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
JSPRJasper Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
TRVITrevi Therapeutics, Inc.
CHRSCoherus BioSciences, Inc.
LYRALyra Therapeutics, Inc.